



Table of contents

Schlingensiepen K.-H.: Editorial (pp. 2080-2080)

Hot Topic: TGF- β As Target in Oncology (Guest Editor: Karl-Hermann Schlingensiepen)

[Click here for article](#)

Hinck A., O'Connor-McCourt M. (pp. 2081-2098)

Structures of TGF- β Receptor Complexes: Implications for Function and Therapeutic Intervention Using Ligand Traps

[Click here for abstract](#)

Ikushima H., Miyazono K. (pp. 2099-2107)

Biology of Transforming Growth Factor- β Signaling

[Click here for abstract](#)

van Meeteren L., Goumans M.-J., ten Dijke P. (pp. 2108-2120)

TGF- β Receptor Signaling Pathways in Angiogenesis; Emerging Targets for Anti-Angiogenesis Therapy

[Click here for abstract](#)

Buijs J., Juarez P., Guise T. (pp. 2121-2137)

Therapeutic Strategies to Target TGF- β in the Treatment of Bone Metastases

[Click here for abstract](#)

Connolly E., Akhurst R. (pp. 2138-2149)

The Complexities of TGF- β Action During Mammary and Squamous Cell Carcinogenesis

[Click here for abstract](#)

Hau P., Jachimczak P., Schlaier J., Bogdahn U. (pp. 2150-2157)

TGF- β 2 Signaling in High-Grade Gliomas

[Click here for abstract](#)

Hilbig A., Oettle H. (pp. 2158-2164)

Transforming Growth Factor Beta in Pancreatic Cancer

[Click here for abstract](#)

Busse A., Keilholz U. (pp. 2165-2175)

Role of TGF- β in Melanoma

[Click here for abstract](#)

Lonning S., Mannick J., McPherson J. (pp. 2176-2189)

Antibody Targeting of TGF- β in Cancer Patients

[Click here for abstract](#)

Ling L., Lee W.-C. (pp. 2190-2202)

TGF-Beta Type I Receptor (Alk5) Kinase Inhibitors in Oncology

[Click here for abstract](#)

Jaschinski F., Rothhammer T., Jachimczak P., Seitz C., Schneider A., Schlingensiepen K.-H. (pp. 2203-2213)

The Antisense Oligonucleotide Trabedersen (AP 12009) for the Targeted Inhibition of TGF- β 2

[Click here for abstract](#)